Literature DB >> 9519895

Proliferation-dependent replication in primary macrophages of macrophage-tropic HIV type 1 variants.

N A Kootstra1, H Schuitemaker.   

Abstract

We previously demonstrated that completion of reverse transcription in macrophages inoculated with the HIV-1 Ba-L variant was established only in the subpopulation of cells with proliferative capacity. In our present study we further extended this observation with three additional HIV-1 isolates, being the macrophage-tropic ADA strain and two primary macrophage-tropic HIV-1 variants isolated from cerebrospinal fluid and from bronchoalveolar lavage from AIDS patients. On inoculation, irrespective of the virus variant used, elongated reverse transcription products could be demonstrated only in macrophages that had proliferated during inoculation as evidenced by the incorporation of bromodeoxyuridine (BrdU), a thymidine analog. The presence of newly synthesized early products of reverse transcription also in the BrdU-negative fraction indicated that viral entry is not disturbed in nondividing cells. Our data indicate that the process of reverse transcription is dependent on cellular conditions that coincide with cell proliferation, and therefore that HIV-1 replication is restricted to cells with proliferative potential.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519895     DOI: 10.1089/aid.1998.14.339

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus.

Authors:  R D Berkowitz; A B van't Wout; N A Kootstra; M E Moreno; V D Linquist-Stepps; C Bare; C A Stoddart; H Schuitemaker; J M McCune
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes.

Authors:  S Neil; F Martin; Y Ikeda; M Collins
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle.

Authors:  N A Kootstra; B M Zwart; H Schuitemaker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1.

Authors:  E Clark; F Santiago; L Deng; S Chong; C de La Fuente; L Wang; P Fu; D Stein; T Denny; V Lanka; F Mozafari; T Okamoto; F Kashanchi
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 6.  Host hindrance to HIV-1 replication in monocytes and macrophages.

Authors:  Anna Bergamaschi; Gianfranco Pancino
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

7.  Human immunodeficiency virus infection inhibits granulocyte-macrophage colony-stimulating factor-induced microglial proliferation.

Authors:  Melissa Cosenza-Nashat; Meng-Liang Zhao; Heather D Marshall; Qiusheng Si; Susan Morgello; Sunhee C Lee
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

8.  HIV-1 activates macrophages independent of Toll-like receptors.

Authors:  Joseph N Brown; James J Kohler; Carter R Coberley; John W Sleasman; Maureen M Goodenow
Journal:  PLoS One       Date:  2008-12-02       Impact factor: 3.240

9.  Inhibition of HIV early replication by the p53 and its downstream gene p21.

Authors:  Binshan Shi; Hamayun J Sharifi; Sara DiGrigoli; Michaela Kinnetz; Katie Mellon; Wenwei Hu; Carlos M C de Noronha
Journal:  Virol J       Date:  2018-03-27       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.